Frisium® 10 mg

FOR A COMPREHENSIVE APPROACH TO SEIZURE CONTROL

Frisium (clobazam) Tablets 10 mg.
THERAPEUTIC CLASSIFICATION Anticonvulsant for adjunctive therapy. INDICATIONS Frisium (clobazam) has been found to be of value as adjunctive therapy in patients with epilepsy who are not adequately stabilized with their current anti-convulsant therapy.

CONTRAINDICATIONS Hypersensitivity to clobazam, severe muscle weakness (myasthenia gravis) and narrow angle glaucoma. WARNINGS Use in the elderly: Frisium (clobazam) should be used with caution in elderly and debilitated patients, and those with organic brain disorders, with treatment initiated at the lowest possible dose. [See Precautions]. Potentiation of drug effects: Patients should be cautioned about the possibility of additive effects when Frisium is combined with alcohol or other drugs with central nervous system depressant effects. Patients should be advised against consumption of alcohol during treatment with Frisium. [See Precautions]. Physical and psychological dependence: Physical and psychological dependence are known to occur in persons taking benzodiazepines. Caution must be exercised if it is at all necessary to administer Frisium to individuals with a history of drug misuse or those who may increase the dose on their own initiative. Such patients must be placed under careful surveillance. Signs and symptoms of withdrawal may follow discontinuation of use of Frisium; thus it should not be abruptly discontinued after prolonged use. [See Precautions]. Use in pregnancy: Frisium should not be used in the first trimester of pregnancy and thereafter only if strictly indicated. Nursing mothers in whom therapy with Frisium is indicated should cease breast-feeding, since clobazam passes into breast milk. Several studies have suggested an increased risk of congenital malformations associated with the use of minor tranquilizers (chlordiazepoxide, diazepam and meprobamate) during the first trimester of pregnancy. If Frisium is prescribed to a woman of child-bearing potential she should be warned to consult her physician regarding the discontinuation of the drug if she intends to become, or suspects she might be, pregnant. Anterograde amnesia: Anterograde amnesia is known to occur after administration of benzodiazepines. Use in patients with depression or psychosis: Frisium is not recommended for use in patients with depressive disorders or psychosis. PRECAUTIONS Driving and Hazardous Activities: Frisium (clobazam) possesses a mild central nervous system depressant effect, therefore patients should be cautioned against driving, operating dangerous machinery or engaging in other hazardous activities, particularly in the dose adjustment period, or until it has been established that they do not become drowsy or dizzy. Use in the Elderly: Elderly and debilitated patients, or those with organic brain syndrome, have been found to be prone to the CNS depressant activity of benzodiazepines even after low doses. Manifestations of this CNS depressant activity include ataxia, oversedation and hypotension. Therefore, medication should be administered with caution to these patients, particularly if a drop in blood pressure might lead to cardiac complications. Initial doses should be low and increments should be made gradually, depending on the response of the patient, in order to avoid oversedation, neurological impairment and other possible adverse reactions. Dependence Liability: Frisium should not be administered to individuals prone to drug abuse. Caution should be observed in all patients who are considered to have potential for psychological dependence. Withdrawal symptoms have been observed after abrupt discontinuation of benzodiazepines. These include irritability, nervousness, insomnia, agitation, tremors, convulsions, diarrhea, abdominal cramps, vomiting and mental impairment. As with other benzodiazepines, Frisium should be withdrawn gradually. Tolerance: Loss of part or all of the anti-convulsant effectiveness of clobazam has been described in patients who have been receiving the drug for some time. There is no absolute or universal definition for the phenomenon and reports vary widely on its development. The reported success of clobazam in intermittent therapy in catamenial epilepsy implies that tolerance may be minimized by intermittent treatment but long-term follow-up is unreported. No studies have identified or predicted which patients are likely to develop tolerance or recisely when this might occur. Use in Mental and Emotional Disorders: It should be recognized that suicidal tendencies may be present in patients with emotional disorders; particularly those depressed. Protective measures and appropriate treatment may be necessary and should be instituted without delay. Since excitement and other paradoxical reactions can result from the use of benzodiazepines in psychotic patients, Clobazam should not be used in patients suspected of having psychotic tendencies. Use in Patients with Impaired Renal or Hepatic Function: Clobazam requires dealkylation and hydroxylation before conjugation. Usual precautions should be taken if Frisium is used in patients who may have some impairment of renal or hepatic function. It is suggested that the dose in such cases be carefully titrated. In patients for whom prolonged


therapy with Frisium is indicated, blood counts and liver function should be monitored periodically. Use in Patients with Acute, Severe Respiratory Insufficiency: In patients with acute, severe respiratory insufficiency, respiratory function should be monitored. Laboratory Tests: If Frisium is administered for repeated cycles of therapy, periodic blood counts and liver and thyroid function tests are advisable. Drug Interactions: Most studies of the potential interactions of clobazam with other anti-epileptic agents have failed to demonstrate significant interactions with phenytoin, phenobarbital, or carbamazepine. However, one study noted that the addition of clobazam caused a 25% increase in serum drug levels in 29% of patients taking carbamazepine, 63% of patients taking phenytoin, 13% of those taking valproate and 14% of those on phenobarbital. The contradictory findings in different studies are presumably due to variations in patient susceptibility, and although clinically significant interactions are unusual, they may occur. Alcohol may also significantly increase plasma clobazam levels. Several of the anti-epileptic agents: carbamazepine, diphenylhydantoin, phenobarbital, valproic acid, cause the blood levels of clobazam to decrease slightly. Findings are less consistent with regard to N-desmethylclobazam: serum levels are lower with concurrent valproic acid, but higher with carbamazepine and diphenylhydantoin. Toxicologic Studies: In mouse, clobazam was associated with hepatomas in high-dose males. In rat, an increased incidence of thyroid adenomas was seen in males. There were three malignancies: two (male and female) in the thyroid and one (female) in the liver. The relevance of these findings to man has not been established. ADVERSE REACTIONS From 19 published studies of Frisium (clobazam) use in epileptic patients, the overall incidence of side-effects was 33% of which drowsiness, dizziness and fatigue were most frequently reported. Canadian experience provides a similar overall incidence (32%) with drowsiness reported in 17.3% of patients, and 12% of patients terminating treatment because of side-effects. The incidence of side-effects was lower in patients under 16 years of age (23.7%) than the incidence in adults (43.1%): p < 0.05, whereas treatment discontinuation incidences were similar across age groups: 10.6% and 13.8% respectively. The following side-effects occurred at incidences of greater than 1% (ataxia [3.9%], weight gain [2.2%], dizziness [1.8%], nervousness [1.6%], behaviour disorder [1.4%], hostility and blurred vision [1.3%]) while other effects occurred at a less than 1% incidence. Symptoms of tiredness may sometimes appear, especially at the beginning of treatment with Frisium and when higher doses are used. Also in rare instances and usually only temporarily, the patient may experience dryness of the mouth, constipation, loss of appetite, nausea, dizziness, muscle weakness, disorientation, tiredness, or a fine tremor of the fingers, but also paradoxical reactions, e.g., restlessness and irritability. After prolonged use of benzodiazepines, impairment of consciousness combined with respiratory disorders has been reported in very rare cases, particularly in elderly patients; it sometimes persisted for some length of time. Under experimental conditions, impairment of alertness has been observed to be less pronounced after therapeutic doses of clobazam than after other benzodiazepines. Nevertheless, even when used as directed, the drug may alter reactivity to such an extent as to impair driving performance or the ability to operate machinery, especially when it is taken in conjunction with alcohol. As with other drugs of this type (benzodiazepines), the therapeutic benefit must be balanced against the risk of habituation and dependence during prolonged use. Isolated cases of skin reactions such as rashes or urticaria have been observed. DOSAGE AND ADMINISTRATION As with other benzodiazepines, the possibility of a decrease in anticonvulsant efficacy in the course of treatment must be borne in mind. In patients with impaired liver and kidney function, Frisium (clobazam) should be used in reduced dosage. Adults: Small doses, 5-15 mg/day, should be used initially, gradually increasing to a maximum daily dose of 80 mg as necessary. Children: In infants (< 2 years), the initial daily dose is 0.5-1 mg/kg/day. The initial dose in children (2-16 years) should be 5 mg/day, which may be increased at 5-day intervals to a maximum of 40 mg/day. As with all benzodiazepines, abrupt withdrawal may precipitate seizures. It is therefore recommended that Frisium be gradually reduced in dose before treatment is discontinued. Administration: If the daily dose is divided, the higher portion should be taken at night. Daily doses up to 30 mg may be taken as a single dose at night. AVAILABILITY Frisium is available as white, uncoated, bevelled, round tablets of 7 mm diameter, marked with 'BGL' above and below the scorebreak on the obverse and the Hoechst 'Tower and Bridge' logo on the reverse. Frisium 10 mg tablets are packaged in blisters of PVC film and aluminium foil and are distributed in packs of 30 [3x10] tablets. Product Monograph available on request.


References: 1 Schmidt D. Clobazam for treatment of intractable epilepsy: A critical assessment. Epilepsia 1994;35(Suppl.5):S92-S95. 2 Canadian Clobazam Cooperative Group. Clobazam in the treatment of refractory epilepsy: The Canadian Experience. A retrospective study. In: Epilepsia 1991, 32(3): 407-416.

Hoechst Marion Roussel

Hoechst Marion Roussel Canada Inc., Laval, Quebec H7L 4A8 A member of the Hoechst Group









Director, Division of Neurology

Department of Medicine

Applications are invited for the position of Director, Division of Neurology, Department of Medicine at the University of Alberta. The Division currently consists of 9 geographic full time neurologists, seven of whom are located at the University of Alberta Hospital site; 10 clinical faculty in neurology exist in the region. Successful neurological research programs exist in fundamental, clinical and community-based research and there is a fully approved postgraduate educational program in neurology. Significant opportunities to recruit faculty exist and are facilitated by the support of the Alberta Heritage Foundation for Medical Research and the Toupin Foundation. Interested applicants should hold an MD and fellowship in the Royal College of Physicians and Surgeons of Canada in Neurology or equivalent and have demonstrated leadership and administrative ability, and clinical expertise along with scholarly accomplishment in research and teaching. The Director will be responsible for the further development and co-ordination of all the Division's programs.

Academic rank and remuneration for this senior position will be commensurate with qualifications and experience. Deadline for applications is 3 January 1997. Please send curriculum vitae and the names and addresses of three references to:

Dr. P.W. Armstrong Chair, Department of Medicine 2F1.30 Walter C. MacKenzie Health Sciences Centre University of Alberta Edmonton, AB, Canada T6G 2R7

The University of Alberta is committed to the principle of equity in employment. As an employer we welcome diversity in the workplace and encourage applications from all qualified women and men, including Aboriginal peoples, persons with disabilities, and members of visible minorities.